Peritoneal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major peritoneal cancer markets are expected to exhibit a CAGR of 18.2% during 2024-2034.
The peritoneal cancer market has been comprehensively analyzed in IMARC's new report titled "Peritoneal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peritoneal cancer, also known as primary peritoneal carcinoma, is a type of cancer that originates in the peritoneum, a thin tissue lining the abdominal cavity. It can present itself with a variety of symptoms, although they can be nonspecific and overlap with other conditions. Some of the common indications associated with the ailment include abdominal pain or discomfort, bloating, changes in bowel habits, unexplained weight loss, fatigue, accumulation of fluid in the abdomen (ascites), loss of appetite, etc. These symptoms may be persistent and progressively worsen over time. The diagnosis of peritoneal cancer typically involves a combination of imaging tests, laboratory analysis, and pathological evaluation. Initially, a healthcare professional may conduct a thorough medical history and physical examination to assess symptoms and identify potential risk factors. Various imaging procedures, such as ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), etc., are commonly used to visualize the abdominal region and locate any abnormalities in the peritoneum. Additionally, laboratory tests are also performed to evaluate tumor markers or specific biomarkers associated with the ailment.
The increasing cases of genetic mutations and alterations in the DNA of peritoneal cells, which lead to uncontrolled cell growth and the development of cancerous tumors, are primarily driving the peritoneal cancer market. In addition to this, the emerging popularity of intraperitoneal chemotherapy, since it allows for high drug concentrations within the peritoneal cavity, thereby targeting cancer cells more effectively, is acting as another significant growth-inducing factor. Moreover, the inflating demand for hyperthermia-based therapies, which involve heating the tumor tissue to enhance the effectiveness of other treatment modalities, is further creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in R&D activities to introduce antibody-drug conjugates (ADCs) that selectively deliver cytotoxic drugs to peritoneal cancer cells while minimizing toxicity to healthy tissues. This, in turn, is also bolstering the market growth. Furthermore, the emerging popularity of nanoparticle-based drug delivery systems on account of their several associated benefits, including enhanced drug delivery to tumor cells, reduced systemic toxicity, sustained release of chemotherapeutic agents, etc., is expected to drive the peritoneal cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the peritoneal cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peritoneal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peritoneal cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the peritoneal cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the peritoneal cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current peritoneal cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the peritoneal cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the peritoneal cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the peritoneal cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of peritoneal cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of peritoneal cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of peritoneal cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with peritoneal cancer across the seven major markets?
What is the size of the peritoneal cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of peritoneal cancer?
What will be the growth rate of patients across the seven major markets?
Peritoneal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for peritoneal cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peritoneal cancer market?
What are the key regulatory events related to the peritoneal cancer market?
What is the structure of clinical trial landscape by status related to the peritoneal cancer market?
What is the structure of clinical trial landscape by phase related to the peritoneal cancer market?
What is the structure of clinical trial landscape by route of administration related to the peritoneal cancer market?
The peritoneal cancer market has been comprehensively analyzed in IMARC's new report titled "Peritoneal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peritoneal cancer, also known as primary peritoneal carcinoma, is a type of cancer that originates in the peritoneum, a thin tissue lining the abdominal cavity. It can present itself with a variety of symptoms, although they can be nonspecific and overlap with other conditions. Some of the common indications associated with the ailment include abdominal pain or discomfort, bloating, changes in bowel habits, unexplained weight loss, fatigue, accumulation of fluid in the abdomen (ascites), loss of appetite, etc. These symptoms may be persistent and progressively worsen over time. The diagnosis of peritoneal cancer typically involves a combination of imaging tests, laboratory analysis, and pathological evaluation. Initially, a healthcare professional may conduct a thorough medical history and physical examination to assess symptoms and identify potential risk factors. Various imaging procedures, such as ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), etc., are commonly used to visualize the abdominal region and locate any abnormalities in the peritoneum. Additionally, laboratory tests are also performed to evaluate tumor markers or specific biomarkers associated with the ailment.
The increasing cases of genetic mutations and alterations in the DNA of peritoneal cells, which lead to uncontrolled cell growth and the development of cancerous tumors, are primarily driving the peritoneal cancer market. In addition to this, the emerging popularity of intraperitoneal chemotherapy, since it allows for high drug concentrations within the peritoneal cavity, thereby targeting cancer cells more effectively, is acting as another significant growth-inducing factor. Moreover, the inflating demand for hyperthermia-based therapies, which involve heating the tumor tissue to enhance the effectiveness of other treatment modalities, is further creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in R&D activities to introduce antibody-drug conjugates (ADCs) that selectively deliver cytotoxic drugs to peritoneal cancer cells while minimizing toxicity to healthy tissues. This, in turn, is also bolstering the market growth. Furthermore, the emerging popularity of nanoparticle-based drug delivery systems on account of their several associated benefits, including enhanced drug delivery to tumor cells, reduced systemic toxicity, sustained release of chemotherapeutic agents, etc., is expected to drive the peritoneal cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the peritoneal cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peritoneal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peritoneal cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the peritoneal cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the peritoneal cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current peritoneal cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the peritoneal cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the peritoneal cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the peritoneal cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of peritoneal cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of peritoneal cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of peritoneal cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with peritoneal cancer across the seven major markets?
What is the size of the peritoneal cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of peritoneal cancer?
What will be the growth rate of patients across the seven major markets?
Peritoneal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for peritoneal cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peritoneal cancer market?
What are the key regulatory events related to the peritoneal cancer market?
What is the structure of clinical trial landscape by status related to the peritoneal cancer market?
What is the structure of clinical trial landscape by phase related to the peritoneal cancer market?
What is the structure of clinical trial landscape by route of administration related to the peritoneal cancer market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PERITONEAL CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PERITONEAL CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PERITONEAL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PERITONEAL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PERITONEAL CANCER - UNMET NEEDS
10 PERITONEAL CANCER - KEY ENDPOINTS OF TREATMENT
11 PERITONEAL CANCER - MARKETED PRODUCTS
11.1 List of Peritoneal Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Lynparza (Olaparib) - AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rubraca (Rucaparib) - Clovis Oncology
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zejula (Niraparib) - Janssen/Merck/GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Avastin (Bevacizumab) - Genentech/Roche
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Elahere (Mirvetuximab soravtansine) - ImmunoGen
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PERITONEAL CANCER - PIPELINE DRUGS
12.1 List of Peritoneal Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Adavosertib - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Guadecitabine - Astex Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ZNc3 - Zentalis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GEN1 - Imunon
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nemvaleukin alfa - Alkermes plc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PERITONEAL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PERITONEAL CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PERITONEAL CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Peritoneal Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Peritoneal Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Peritoneal Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Peritoneal Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Peritoneal Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Peritoneal Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Peritoneal Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Peritoneal Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Peritoneal Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Peritoneal Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Peritoneal Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Peritoneal Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Peritoneal Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Peritoneal Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Peritoneal Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Peritoneal Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Peritoneal Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Peritoneal Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Peritoneal Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Peritoneal Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Peritoneal Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Peritoneal Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Peritoneal Cancer - Access and Reimbursement Overview
16 PERITONEAL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PERITONEAL CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PERITONEAL CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PERITONEAL CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PERITONEAL CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PERITONEAL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PERITONEAL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PERITONEAL CANCER - UNMET NEEDS
10 PERITONEAL CANCER - KEY ENDPOINTS OF TREATMENT
11 PERITONEAL CANCER - MARKETED PRODUCTS
11.1 List of Peritoneal Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Lynparza (Olaparib) - AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rubraca (Rucaparib) - Clovis Oncology
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Zejula (Niraparib) - Janssen/Merck/GlaxoSmithKline
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Avastin (Bevacizumab) - Genentech/Roche
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Elahere (Mirvetuximab soravtansine) - ImmunoGen
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PERITONEAL CANCER - PIPELINE DRUGS
12.1 List of Peritoneal Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Adavosertib - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Guadecitabine - Astex Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ZNc3 - Zentalis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 GEN1 - Imunon
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nemvaleukin alfa - Alkermes plc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PERITONEAL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PERITONEAL CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PERITONEAL CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Peritoneal Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Peritoneal Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Peritoneal Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Peritoneal Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Peritoneal Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Peritoneal Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Peritoneal Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Peritoneal Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Peritoneal Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Peritoneal Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Peritoneal Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Peritoneal Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Peritoneal Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Peritoneal Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Peritoneal Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Peritoneal Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Peritoneal Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Peritoneal Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Peritoneal Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Peritoneal Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Peritoneal Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Peritoneal Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Peritoneal Cancer - Access and Reimbursement Overview
16 PERITONEAL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PERITONEAL CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PERITONEAL CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
